Purchase this article with an account.
G.G. Emerson, S. Nolte, D.J. Wilson, J.T. Stout, C.J. Flaxel, A.K. Lauer, M.L. Klein; Results ff Optical Coherence Tomography During Pegaptanib (Macugen) Therapy For Neovascular Age–Related Macular Degeneration . Invest. Ophthalmol. Vis. Sci. 2006;47(13):5242.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate macular thickness measured by optical coherence tomography (OCT) during pegaptanib therapy for neovascular age–related macular degeneration (AMD).
Intravitreous pegaptanib (1 mg) injections were repeated every 6 weeks (n = 40 eyes from 40 patients). The primary outcome measure was central macular thickness measured by OCT. Secondary outcomes were fluorescein angiographic leakage and visual acuity.
Thickness of the central area on OCT decreased from 340 ± 24 µm to 280 ± 20 µm (P = 0.02) over the first 24 weeks of pegaptanib injections. During the same time period, fluorescein angiograms with definite leakage decreased from 100% to 54%, and visual acuity was stable (20/117 vs. 20/127; P = 0.7).
Central macular thickness secondary to neovascular AMD responds modestly to intravitreal injections of pegaptanib at 6–week intervals.
This PDF is available to Subscribers Only